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ABSTRACT
Background. Prophylactic central neck dissection (CND)
remains controversial in papillary thyroid carcinoma (PTC).
Because postsurgical stimulated thyroglobulin (sTg) level
is a good surrogate for recurrence, the study aimed to
evaluate the impact of prophylactic CND on preablative and
postablative sTg levels after total thyroidectomy.
Methods. Of the 185 patients retrospectively analyzed, 82
(44.3%) underwent a total thyroidectomy and prophylactic
CND (CND-positive group) while 103 (55.7%) underwent
total thyroidectomy only (CND-negative group). All
patients had no preoperative or intraoperative evidence of
lymph node metastases. Clinicopathological characteristics,
postoperative outcomes, and preablative and postablative
sTg levels were compared between the two groups. Preab-
lative sTg level was taken at the time of radioiodine
ablation, while postablative sTg level was taken 6 months
after ablation. A multivariable analysis was conducted
to identify factors for preablative athyroglobulinemia
(sTg \ 0.5 lg/L).
Results. Relative to the CND-negative group, the CND-
positive group had larger tumors (15 mm vs. 10 mm,
P \ 0.005), more extrathyroidal extension (26.8% vs.
14.6%, P \ 0.003), more tumor, node, metastasis system
stage III disease (32.9% vs. 9.7%, P \ 0.001), and more
temporary hypoparathyroidism (18.3% vs. 8.7%, P =
0.017). Fourteen patients (17.1%) in the CND-positive group
were upstaged from stages I/II to III as a result of prophy-
lactic CND. The CND-positive group experienced lower
median preablative sTg (\0.5 lg/L vs. 6.7 lg/L, P \ 0.001)
and a higher rate of preablative athyroglobulinemia (51.2%
vs. 22.3%, P = 0.024), but these differences were not
observed 6 months after ablation. Prophylactic CND was the
only independent factor for preablative athyroglobulinemia.
Conclusions. Although performing prophylactic CND in
total thyroidectomy may offer a more complete initial
tumor resection than total thyroidectomy alone by mini-
mizing any residual microscopic disease, such a difference
becomes less noticeable 6 months after ablation.
Papillary thyroid carcinoma (PTC) is the most common
type of differentiated thyroid carcinoma. Its age-adjusted
incidence has doubled over the last 25 years.1 Despite its
relatively good prognosis with a 10-year cancer-specific
survival above 90%, locoregional recurrence is common.2
With recognition of the concept of stepwise progression of
lymph node metastasis originating from the central (level VI)
to the lateral compartment (levels II–V), a growing number
of surgeons are performing routine prophylactic central neck
dissection (CND) at the time of the thyroidectomy for PTC.3
However, its routine practice remains controversial.4–10 The
arguments for it include improved pathological staging
accuracy, preoperative failure to reliably detect central
lymph node metastasis, and avoidance of central compart-
ment reoperations.3,4,11 On the other hand, arguments
against it include increased surgical morbidities such as
hypoparathyroidism and recurrent laryngeal nerve (RLN)
injury; most important of all, prophylactic CND has not been
shown to reduce recurrence or mortality rate.9,10,12–14 There
have been no randomized, controlled studies showing that
prophylactic CND reduces recurrence or improves sur-
vival.10 Furthermore, most studies to date have been
relatively underpowered with short follow-up periods, and
a recent meta-analysis also failed to demonstrate lower
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recurrence rates in patients who routinely underwent pro-
phylactic CND.5
To overcome these problems, some authors have com-
pared the postoperative stimulated thyroglobulin (sTg)
level between those who had prophylactic CND and those
who did not.6,15,16 Because Tg is produced solely by dif-
ferentiated thyroid follicular cells, measuring serum sTg
could potentially help in the detection of residual, recur-
rent, or metastatic disease. Studies have found postsurgical
sTg levels could reliably predict disease outcomes.4,17–19
However, to our knowledge, there have been few studies
assessing the impact of prophylactic CND on postsurgical
sTg, and their results had not been consistent.6,15,16 Fur-
thermore, few studies have evaluated the relationship
between preablative and postablative sTg in the setting of
patients who routinely undergo prophylactic CND.6,16,20
We hypothesized that patients who underwent a total
thyroidectomy and prophylactic CND would have lower
preablative sTg levels as a reflection of the better surgical
completeness than those who underwent total thyroidec-
tomy alone. Our study aimed to evaluate the impact of
prophylactic CND on preablative and postablative sTg in
PTC after total thyroidectomy.
PATIENTS AND METHODS
Patients
From 2004 to 2010, a total of 257 consecutive patients
with PTC underwent surgery at our institution. All patients
were operated by the same team of endocrine surgeons.
For the purpose of the study, patients who required a
concomitant lateral neck dissection (n = 32) or were diag-
nosed with clinically occult microcarcinoma (n = 40) were
excluded. After excluding these patients, 185 patients were
retrospectively analyzed. All patients had no evidence of
central lymph node metastases preoperatively on ultra-
sound (US) or at the time of operation. Patients with
obviously enlarged central lymph nodes requiring a thera-
peutic CND were not included. All operations were
performed by two endocrine surgeons. The decision for a
prophylactic unilateral CND was based on the personal
preference of the operating surgeon and not based on tumor
size or other tumor characteristics. Nevertheless, there was
an increasing tendency to perform more prophylactic CND
in the latter part of the study period.
In terms of patient characteristics, most were women
(78.4%) and ethnic Chinese (96.8%). The median age of
operation was 51.0 (range 17.1–90.6) years, and the median
follow-up period was 26.0 (range 9.7–101.2) months.
Eighty-two patients (44.3%) underwent a total thyroidec-
tomy and prophylactic CND (CND-positive group), while
103 (55.7%) underwent a total thyroidectomy only (CND-
negative group). All relevant clinical, laboratory, radio-
logic, and perioperative data were collected prospectively,
and follow-up data were regularly updated in a computer-
ized thyroid database. The present study protocol was
approved by the local institutional review board. Patient
demographics, biochemical profile, operative findings,
surgical approach, and postoperative outcomes were com-
pared between the two groups.
Management of PTC
Details of surgical treatment, criteria for radioiodine
(RAI) ablation, postoperative care, and follow-up protocol
had been described previously.21 In brief, total thyroidec-
tomy has been the preferred procedure for all patients with
a preoperative diagnosis of PTC. A prophylactic CND was
performed immediately after the completion of the total
thyroidectomy and consisted of the removal of all nodes
and fibro-fatty tissue extending vertically from the hyoid
bone to the thoracic inlet and laterally from the medial
border of common carotid artery to the midline of the
trachea. A frozen section of central lymph nodes was not
routinely performed. The ipsilateral RLN was mobilized
and skeletonized along its entire cervical course. An
intraoperative nerve stimulator was used to confirm the
functional integrity of RLN.22 Autotransplantation of any
inadvertently removed parathyroid glands was readily
performed. sTg was defined as a Tg level measured in the
presence of thyroid-stimulating hormone (TSH) of [30
mIU/L either by 4-week thyroxine withdrawal or recom-
binant TSH injections. Postoperative sTg levels were taken
approximately 2 months after surgery (or at the time of
RAI ablation) and again 8–9 months after surgery (or 6
months after RAI ablation, usually at the time of the whole-
body scan). Tg autoantibodies were measured at the same
time. The decision for RAI ablation was based on the
presence of risk factors including tumor size[1 cm, lymph
node metastasis, age [45 years old, extrathyroidal exten-
sion, macroscopic postoperative residual disease in the
neck, and distant metastasis. It was not based on the pre-
ablative sTg level. Three gigabecquerels or 80 mCi I131
was the standard fixed ablative dose, while subsequent I131
therapy was performed with 5.5 GBq (or 150 mCi). TSH
suppression to below \0.1 lg/L was recommended for
high- and intermediate-risk patients.
Postoperative Care and Follow-up Protocol
Serum calcium and phosphate levels were measured
within 6 h and every 12 h after the operation until stabi-
lized. Calcium with or without vitamin D supplements was
prescribed for symptomatic hypocalcemia or a calcium
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level \1.70 mmol/L. Those who could discontinue sup-
plements in the presence of normocalcemia within 6
months after surgery were categorized as having temporary
hypoparathyroidism, whereas those needed supplements for
[6 months together with a below-normal serum parathy-
roid hormone level were considered to have permanent
hypoparathyroidism. Perioperative direct laryngoscopy was
performed before and within 1 week after the operation to
assess vocal cord function. RLN palsy lasting [6 months
after thyroidectomy as documented by direct laryngoscopy
was regarded as permanent. To calculate transient and
permanent RLN palsy rates, the number of nerves at risk
was used.
After surgery, all patients were followed up within 4
weeks in a specialized combined surgical oncology clinic.
A follow-up visit was conducted at 3-month intervals in the
first 2 years, 6-month intervals in the subsequent 3 years,
and annually thereafter. Clinical examination, neck US,
and nonstimulated Tg levels were assessed during follow-
up visits. Locoregional recurrence was defined as macro-
scopic disease at clinical examination or US that was not
present at the initial presentation.
Laboratory Methods
All postoperative serum Tg levels were measured at the
same laboratory with the same immunometric assay. The
assay used was the Immulite 2000 (Diagnostic Products;
Roche, Los Angeles, CA). This was calibrated against the
CRM-457 standard. A sTg level of \0.5 lg/L was consid-
ered undetectable or athyroglobulinemia. Normal reference
range was\0.5–55 lg/L, and sensitivity was\0.2 lg/L.
Statistical Analysis
Statistical analysis was performed by the chi-square test
or by Fisher’s exact test to compare categorical variables,
and the Mann–Whitney U-test was used to compare con-
tinuous variables between groups. Continuous variables
were expressed as medians with ranges. Variables that
were significant in the univariate analysis were entered into
multivariate analysis. To improve clinical utility, before
entering into the multivariate analysis, significant contin-
uous variables were converted into binary variables by
using the overall median value as the cutoff. Binary logistic
regression analysis with a variable entrance criterion of
0.05 or less was conducted to identify factors associated
with preablative athyroglobulinemia after surgery. To
evaluate the correlation between the number of lymph
nodes retrieved and preablative sTg level, the Spearman
rank correlation test was performed. All statistical analyses
were performed by SPSS software, version 18.0 (SPSS,
Chicago, IL).
RESULTS
Table 1 shows a comparison of patient clinicopatho-
logical features, tumor, node, metastasis system (TNM)
tumor stages, and MACIS (metastases, age, completeness
of surgery, invasion, and size) score between the CND-
positive and CND-negative groups. Age at operation, sex,
and clinical presentation were similar between the two
groups. When compared to the CND-negative group, the
median tumor size was significantly larger (15 mm vs. 10
mm, P \ 0.005) and the incidence of extrathyroidal
extension was significantly higher in the CND-positive
group (26.8% vs. 14.6%, P \ 0.003). However, the inci-
dence of tumor multifocality, capsular invasion, coexisting
thyroiditis, and MACIS scores were comparable in the two
groups. In terms of TNM stages, there was a significantly
higher proportion belonging to tumor stage III (32.9% vs.
9.7%, P \ 0.001) but a smaller proportion belonging to
tumor stage I (48.8% vs. 76.7%, P \ 0.001) in the CND-
positive group. As expected, the median number of central
lymph nodes retrieved, number of central lymph nodes
involved, and proportion of patients with metastatic central
compartment lymph nodes (pN1a) were significantly
greater in the CND-positive group. Five patients in the
CND-negative group had one perithyroidal lymph node
removed, and all (100%) turned out to be metastatic,
whereas in the CND-positive group, 45 patients (54.9%)
had pN1a-positive tumor. Ectopic thyroid tissue or thyroid
rests were not found in any of the central compartment
specimens examined. Among those belonging to TNM
stage III, there were 14 patients (17.1%) in the CND-
positive group and 4 patients (3.9%) in the CND-negative
group who had pT1 or pT2 on histology. This meant that as
a result of prophylactic CND, tumors of 12.7% of patients
were upstaged from TNM stages I/II to III. Table 2 com-
pares postoperative complications and incidence of
parathyroid autotransplantation between the CND-positive
and CND-negative groups. The rate of temporary hypo-
parathyroidism was significantly higher in the CND-
positive group (18.3% vs. 8.7%, P = 0.017). Rates of RLN
injury, permanent hypoparathyroidism, bleeding, and
wound infection were similar between the two groups. The
percentage of parathyroid autotransplantation was signifi-
cantly higher in the CND-positive group (37.8% vs. 19.4%,
P = 0.008)
Table 3 shows a comparison of RAI ablation, postop-
erative Tg levels, follow-up period, and recurrence rate
between the CND-positive and CND-negative groups. In
the CND-positive group, there was a significantly higher
proportion of patients receiving RAI ablation (75.6% vs.
68.0%, P = 0.023). The CND-positive group had a sig-
nificantly lower median preablative sTg level (\0.5 lg/L
vs. 6.7 lg/L, P \ 0.001) and a higher rate of preablative
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athyroglobulinemia (51.2% vs. 22.3%, P = 0.024). Fur-
thermore, there was a significant inverse association
between the number of central lymph nodes retrieved and
the preablative sTg level (q = -0.252, P = 0.020).
However, 6 months after RAI ablation, the median sTg
level and the proportion of athyroglobulinemia became
comparable between the two groups. The proportion of
detectable sTg 6 months after ablation was similar between
the two groups (P = 0.292). Follow-up duration and recur-
rence rate were comparable in the two groups. In both
groups, all six locoregional recurrences occurred in the
lateral (or noncentral) neck compartment. The time to
recurrence ranged 28.3–56.9 months. There was one distant
recurrence detected in the lung on fludeoxyglucose–posi-
tron emission tomographic scan in the CND-negative group
at 30.7 months.
Figure 1 shows a breakdown of the number of unde-
tectable and detectable sTg level in the CND-positive and
CND-negative groups before and 6 months after ablation.
Among patients with detectable sTg before ablation, those
in the CND-negative group were significantly more likely
to become athyroglobulinemia than those in the CND-
positive group (49/57 vs. 21/37, P = 0.003)
Table 4 shows the multivariable analysis for unde-
tectable sTg level after surgery before ablation. Although
both tumor size and extrathyroidal extension were sig-
nificant in the univariate analysis, they were not entered
into the multivariable analysis because they were already
represented by TNM stages. After adjusting for other
TABLE 1 Comparison of
patient clinicopathologic
features, TNM stage, and
MACIS score between those
who underwent a routine CND
(CND-positive group) and those
who did not (CND-negative
group)
Continuous variables are
expressed as median (range);
categorical variables are
expressed as n (%)
PTC papillary thyroid
carcinoma, TNM tumor, node,
metastasis system (6th edition),
LN lymph node, MACIS
metastases, age, completeness
of surgery, invasion, and size
Characteristic CND-positive
group (n = 82)
CND-negative
group
(n = 103)
P value
Age at operation (y) 52.0 (17.1–79.2) 50.0 (26.2–90.8) 0.304
Sex 1.000
Male 18 (22.0) 22 (21.4)
Female 64 (78.0) 81 (78.6)
Presented as a palpable swelling 56 (68.3) 79 (76.7) 0.201
Tumor characteristics
Tumor size (mm) 15 (2–90) 10 (2–110) 0.005
Multifocality 30 (36.6) 28 (27.2) 0.179
Capsular invasion 18 (22.0) 25 (24.3) 0.750
Extrathyroidal extension 22 (26.8) 15 (14.6) 0.033
Coexisting thyroiditis 16 (19.5) 12 (11.7) 0.352
TNM PTC stage \0.001
I 40 (48.8) 79 (76.7)
II 7 (8.5) 6 (5.8)
III 27 (32.9) 10 (9.7)
IV 8 (9.8) 8 (7.8)
No. of central LNs retrieved 5 (2–18) 0 (0–1) \0.001
No. of positive central LNs excised 1 (0–8) 0 (0–1) \0.001
No. of patients with metastatic central compartment LNs
(pN1a)
45 (54.9) 5 (4.9) \0.001
MACIS score 4.84 (2.18–11.34) 4.55 (3.13–9.80) 0.089
TABLE 2 Comparison of postoperative complications and incidence
of parathyroid autotransplantation between those who underwent a
routine CND (CND-positive group) and those who did not (CND-
negative group)
Complication CND-positive
group (n = 82),
n (%)
CND-negative
group (n = 103),
n (%)
P value
RLN injurya
Temporary 3 (1.8) 0 (0.0) 0.324
Permanent 1 (0.6) 1 (0.5) 0.443
Hypoparathyroidism
Temporary 15 (18.3) 9 (8.7) 0.017
Permanent 2 (2.4) 1 (1.0) 1.000
Bleeding 0 (0.0) 1 (1.0) 1.000
Wound infection 0 (0.0) 0 (0.0) 1.000
Parathyroid
autotransplantation
31 (37.8) 20 (19.4) 0.008
CND central neck dissection, RLN recurrent laryngeal nerve
a Calculated on the basis of the number of nerves at risk
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significant factors, prophylactic CND turned out to be the
only independent factor for preablative athyroglobulin-
emia (odds ratio 3.60, 95% confidence interval 1.12–
11.55).
DISCUSSION
Despite its increasing popularity, adopting routine pro-
phylactic CND remains controversial because studies have
not demonstrated a clear advantage of prophylactic CND in
improving disease outcomes.4–10 Given the relatively slow
tumor growth and excellent prognosis associated with PTC,
a prospective study of sufficient size would be required to
evaluate the impact of prophylactic CND on disease out-
comes. Both preablative and postablative sTg levels have
been shown to be excellent surrogate markers and predic-
tors for disease-free emission and disease-specific survivals
in PTC.4,17–19 Preablative sTg was shown to have potential
application in modulating RAI ablation and stratifying
follow-up strategy.19 Furthermore, disease recurrence has
been redefined as disease measurable by elevated Tg levels
and/or on US and not solely on the basis of whole-body
scan.4 As a result of this paradigm shift, achieving athy-
roglobulinemia has become an important issue for patients
with PTC after surgery.4 Sywak et al. examined the asso-
ciation between prophylactic CND and sTg and found that
prophylactic CND could lower postablative sTg and
achieve a higher rate of athyroglobulinemia than those who
did not undergo prophylactic CND.15 The same group
subsequently showed that the number of central lymph
nodes retrieved significantly inversely correlated with sTg
levels 1 year after ablation.16 However, because the pos-
tablative sTg level not only depends on the completeness of
the initial surgery but also on the ablative effect of RAI on
residual microscopic disease present within the central
compartment as well as areas outside it, our study aimed to
specifically evaluate the impact of additional prophylactic
CND on preablative and postablative sTg levels.6
Despite the far larger size and more advanced stages of
PTC, our study found that the CND-positive group had a
much lower median preablative sTg level and experienced
TABLE 3 Comparison of
radioiodine ablation,
postoperative thyroglobulin
levels, follow-up period, and
recurrence rate between those
who underwent a routine CND
(CND-positive group) and those
who did not (CND-negative
group)
Continuous variables are
expressed as median (range);
categorical variables are
expressed as n (%)
CND central neck dissection, Tg
thyroglobulin level, TSH
thyroid-stimulating hormone
Characteristic CND-positive
group (n = 82)
CND-negative
group (n = 103)
P value
RAI ablation 0.023
Provided 62 (75.6) 63 (68.0)
Not provided 20 (24.4) 40 (32.0)
Preablation (2 months after surgery)
TSH level (mIU/L) 51.0 (30.5–331.0) 61.5 (33.2–145.0) 0.959
Stimulated Tg level (lg/L) \0.5 (\0.5–480.0) 6.70 (\0.5–140.0) \0.001
No. of athyroglobulinemia 42 (51.2) 23 (22.3) 0.024
Postablation (8 months after surgery)
TSH level (mIU/L) 66.5 (33.8–129.5) 73.5 (33.3–126.5) 0.125
Stimulated Tg level (lg/L) \0.5 (\0.5–480.0) \0.5 (\0.5–800.0) 0.787
No. of athyroglobulinemia 63 (76.8) 72 (69.9) 0.292
Nonstimulated Tg level on last visit (lg/L) \0.5 (\0.5–325.0) \0.5 (\0.5–495.0) 0.304
Follow-up period (mo) 25.5 (9.7–77.1) 27.1 (10.7–101.2) 0.307
First recurrence site 1.000
Locoregional 3 (3.7) 3 (2.9)
Distant 0 (0.0) 1 (1.0)
FIG. 1 Chart showing the breakdown of the number of undetectable
and detectable stimulated thyroglobulin (sTg) between those who
underwent a prophylactic central neck dissection (CND-positive
group) and those who did not (CND-negative group) in the
preablation period and 6 months after radioiodine (RAI) ablation.
RAI? RAI ablation provided, RAI- no RAI ablation provided
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a higher rate of preablative athyroglobulinemia than the
CND-negative group. In fact, about 50% of patients had
undetectable sTg level in the CND-positive group before
ablation as compared to 22.3% in the CND-negative group.
This implied that the addition of prophylactic CND may
provide a more complete surgical excision by leaving less
amount of residual microscopic disease behind as reflected
by the lower sTg level. Although detectable levels of sTg
without ablation could potentially come from the presence
of thyroid remnants or thyroid rests not removed at the time
of initial surgery rather than from the residual microscopic
disease, we believe that because the same thyroidectomy
procedure was performed during the study period, regard-
less of whether or not prophylactic CND was performed,
the volume of the thyroid remnant would be comparable
between the two groups. Furthermore, we did not find the
presence of any ectopic thyroid tissue or thyroid rests in
any of the central compartment specimen, although this
was believed to be present in up to 20% of cases.23 Perhaps
this might be because the thymus was not removed in our
prophylactic CND. Therefore, we postulated that perhaps
prophylactic CND was able to remove any subclinical or
microscopic disease present in the central lymph nodes
leading to the lower level of preablative sTg. This was
somewhat supported by the fact that [50% of the central
lymph nodes excised contained metastatic PTC; similar
rates have been reported by other authors.6–8,14 In further
support of this finding, our data found a statistically sig-
nificant inverse correlation between the number of lymph
nodes retrieved and preablative sTg levels, and in the
multivariable analysis, after adjusting for age, sex, tumor
stage, and number of lymph nodes retrieved, prophylactic
CND was an independent significant factor for achieving
preablative athyroglobulinemia. We believed that these
findings may provide indirect evidence that the addition of
prophylactic CND at the time of total thyroidectomy offers
a more complete local resection of the PTC by removing
subclinical or microscopic residual disease, presumably
harbored within the central compartment. However, it was
interesting to note that 6 months after ablation, the median
sTg level and rate of athyroglobulinemia became compa-
rable in the two groups, and among those with detectable
preablative sTg who received RAI ablation (n = 120), the
CND-negative group were significantly more likely to
become athyroglobulinemic than those the CND-positive
group (P = 0.003). Perhaps this means that the residual
disease not removed in the central compartment in the
CND-negative group was still able to be completely abla-
ted and thus a similar overall rate of postablative
athyroglobulinemia was experienced as the CND-positive
group. However, the question of whether RAI ablation
could make up for the less complete surgery (i.e., without
CND) is debatable and is beyond the scope of the study.
Another interesting observation was tumor upstaging as
a result of prophylactic CND, leading to higher doses and
frequency of RAI ablation, as reported by other authors.6–8
Although a difference in RAI dose per patient was not
observed because we adopted a fixed-dose protocol, we did
observe a far higher frequency of RAI ablation in the CND-
positive group. This was presumably related to the higher
incidence of pN1a in the CND-positive group, leading to
upstaging of 12.7% PTC from stages I/II to III. This was in
concordance with other authors.6–8,24
Although prophylactic CND resulted in a far higher
temporary hypoparathyroidism rate, we believe that the
unilateral prophylactic CND was associated with accept-
able level of complications and was a good compromise
between achieving completeness of surgery and reducing
patient morbidity because this has been advocated by other
groups.15,16 We believe that performing bilateral prophy-
lactic CND may further increase patient morbidities
because of the risk of damaging the contralateral inferior
parathyroid gland and RLN. In our opinion, a more liberal
use of parathyroid autotransplantation at the time of pro-
phylactic CND could reduce the rate of permanent
hypoparathyroidism.25 An alternative strategy to reduce the
overall surgical morbidity would be to adopt a selective
approach, where only patients with certain prognostic
factors associated with subclinical central lymph node
TABLE 4 Multivariable analysis of preoperative clinicopathological
factors for preablative undetectable stimulated thyroglobulin level or
athyroglobulinemia after surgery
Covariate Odds
ratio
95% confidence
interval
P value
Age at operation (y) 0.652–4.533 0.273
\50 1
C50 1.719
Sex 0.737–8.110 0.144
Male 1
Female 2.445
Stage of PTC by TNM 0.317–2.438 0.804
Tumor stages I/II 1
Tumor stages III/IV 0.804
Prophylactic central neck
dissection
1.124–11.549 0.031
No 1
Yes 3.603
No. of central lymph nodes
retrieved
0.305–3.049 0.951
B4 1
[4 0.965
PTC papillary thyroid carcinoma, TNM tumor, node, metastasis sys-
tem (6th edition)
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metastasis would undergo prophylactic CND. A recent
study found that male sex, tumor multifocality, and extra-
thyroidal extension were predictors for subclinical central
lymph node metastasis.26
Our data should be interpreted cautiously because this was
a relatively moderate-size retrospective study, which tends
to limit the power of the study to identify smaller effects such
as rate of recurrence and permanent hypoparathyroidism.
Also, because this was not a randomized study, it was prone
to selection biases. One important selection bias was that it
was difficult to know whether the CND-positive group also
included some patients with slightly suspicious intraopera-
tive central lymph nodes because the decision was at the
discretion of the operating surgeon. Also, it would be inter-
esting to evaluate the difference in significance between
micro- and macrometastases in the central lymph nodes in
the future. Although sTg is a good surrogate marker, the
clinical significance of mildly detectable sTg remains
unknown, and it was observed that such detectable levels
may spontaneously decrease over time.27,28
Despite having larger-size and more advanced PTCs, the
CND-positive group had a much lower median sTg level
and a higher rate of athyroglobulinemia before ablation
than the CND-negative group, but 6 months after ablation,
these differences were no longer observed. On the basis of
these findings, although the addition of prophylactic CND
for PTC may provide a more complete initial resection than
total thyroidectomy alone by minimizing the amount of
microscopic residual disease, differences between the two
procedures become less noticeable 6 months after RAI
ablation.
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